TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05574803

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Active-tDCS
Description: Active-tDCS (1 mA) over the supplementary motor area (SMA) for 5 sessions (20 minutes per session, weekly), along with behavioural therapy of speaking tasks (i.e., story narration and conversation) using the minimum prolongation technique based on the Camperdown Program.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham-tDCS
Description: Sham-tDCS (1 mA) over the supplementary motor area (SMA) for 5 sessions (one minutes per session, weekly), along with behavioural therapy of speaking tasks (i.e., story narration and conversation) using the minimum prolongation technique based on the Camperdown Program. Participants will receive initial stimulation for one minute, eliciting a tingling sensation on the scalp then it will be discontinued.
Study: NCT05190822

Intervention type: OTHER
Intervention: College student
Description: Our research will be conducted by face-to-face interviews within the scope of questionnaires prepared by us for students studying in departments other than Physiotherapy and Rehabilitation at Acibadem Mehmet Ali Aydinlar University.
Study: NCT04948034

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Ablative Radiotherapy (SABR)
Description: We plan to irradiate as many metastatic lesions as possible, in the precondition that normal tissues can tolerate.~Target dose will be adjusted depending on site of the lesion and organs at risk (BED \> 100Gy).~Treatment schedule is once per day and five days per week. Sequence of irradiation for multiple metastases is at the discretion of the investigators based on their experience.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fruquintinib
Description: Starts within two weeks upon SABR completion: 5mg, d1-14, qd; Continued until disease progression, unacceptable toxicity or patient withdrawal.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tislelizumab
Description: Starts within one week upon SABR completion: 200mg, d1, q3w; the dosing will continue for up to two years until disease progression, unacceptable toxicity or patient withdrawal.
Study: NCT05351541

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Psilocybin therapy with Zolpidem and Modafinil
Description: 1-30 mg (oral administration), Modafinil (oral administration), and Zolpidem (oral administration)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Psilocybin therapy with Zolpidem
Description: 1-30 mg (oral administration), Zolpidem (oral administration), and placebo (oral administration)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Psilocybin therapy with Modafinil
Description: 1-30 mg (oral administration), Modafinil (oral administration), and placebo (oral administration)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Psilocybin therapy with Placebo
Description: 1-30 mg (oral administration), and placebo (oral administration)
Study: NCT06477250

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Empathy-based socio-emotional mental training
Description: The goal of the EmCo dyad practice is to enhance coping with difficult emotions, empathic and compassionate listening, social sharing, acceptance, and gratitude. It involves a daily partner-based practice and weekly coaching sessions with expert teachers.
Study: NCT06264752

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Level A
Description: Pharmacy personnel will generate a general recommendation based on the AKI KDIGO management guidelines to the physician.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Level B
Description: The pharmacist will make nephrotoxic/renally eliminated medication management recommendations to the attending physician (or designee). Recommendations may include stopping or changing a drug, changing dose or schedule, ordering laboratory tests, taking no action, or other. The pharmacist will record details of the interaction with the physician and whether recommendations were accepted.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Passive Alert
Description: Passive Cerner alert provides decision support within the EMR for the diagnosis and basic staging of AKI but without specific recommendations for management.
Study: NCT05766345

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BCG-Vaccine SSI [Statens Serum Institut]) Danish strain 1331
Description: Nothing to add

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Nothing to add
Study: NCT04272827

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Liposuction
Description: Liposuction treatment will be performed according to the study protocol using the wet technique depending on the amount of fat to be removed, if necessary in several sessions.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Liposuction
Description: Liposuction treatment will be performed according to the study protocol using the wet technique depending on the amount of fat to be removed, if necessary in several sessions.
Study: NCT05561946

Intervention type: DEVICE
Intervention: Owlet OSS 3.0
Description: The Owlet OSS 3.0 is worn continuously for a minimum of 48 hours and the skin where the device is worn is monitored for any skin injury/irritation

Intervention type: DEVICE
Intervention: Owlet OSS 3.0
Description: The Owlet OSS 3.0 is worn continuously for a minimum of 48 hours and the skin where the device is worn is monitored for any skin injury/irritation
Study: NCT04981093

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone Injection
Description: Intravenous injection after induction of anesthesia~Injection 0.15mg/kg dexamethasone (2ml)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: 2ml of normal saline was injected intravenously after induction of anesthesia
Study: NCT04954716

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Deep Neck Flexor Massage
Description: Deep friction massage is a specific connective tissue massage that was given across the affected fibers.The therapist's fingers and patient's skin must move as one, otherwise moving subcutaneous fascia against muscle or ligament could lead to blister formation or subcutaneous bruising.The friction massage must have sufficient sweep and be deep enough.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Post-Isometric Relaxation Technique
Description: The PIR technique is performed as follows.The hypertonic muscle is taken to a length just short of pain, or to the point where resistance to movement is first noted.A submaximal (10-20%) contraction of the hypertonic muscle is performed away from the barrier for between 5 and 10 seconds and the therapist applies resistance in the opposite direction . The patient should inhale during this effort.After the isometric contraction the patient is asked to relax and exhale while doing so.Following this a gentle stretch is applied to take up the slack till the new barrier.Starting from this new barrier, the procedure is repeated two or three times.
Study: NCT06479447

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PORTAL-PTSD
Description: Patients will be eligible if they are 18+ years, have had a primary care visit in the last 2 years, and have not been screened for PTSD in the last year. The validated PC-PTSD-5 (Primary Care Post Traumatic Stress Disorder-5) screener will be used. Clinics will implement visit-based and population health screening for patients enrolled in the patient portal who have not been screened for PTSD in the last year and have had a clinic appointment in the last 2 years. The PCBH care manager or patient navigator will follow-up with patients every 2 weeks to ensure they have been connected to care and re-measure their PTSD symptoms. The follow-up calls will continue until symptom remission, after which follow-ups will occur quarterly for 6 months. Primary care clinicians will receive training on trauma-informed care and PTSD management, and will be surveyed at baseline, immediately after training, and 6 months-post intervention to evaluate changes in their knowledge of trauma-informed care.
Study: NCT06274450

Intervention type: COMBINATION_PRODUCT
Group type: OTHER
Intervention: skin care product
Description: Subjects are uniformly using skin care products provided by the sponsor during the test. Skin care product include: WINONA sensitiveness relieving moisturizing cleansing foam, WINONA sensitiveness relieving moisturizing lotion, WINONA anti-sensitive tolerance-extreme moisturizing cream

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: skin care product
Description: Subjects are uniformly using skin care products provided by the sponsor during the test. Skin care product include: WINONA sensitiveness relieving moisturizing cleansing foam, WINONA sensitiveness relieving moisturizing lotion, WINONA anti-sensitive tolerance-extreme moisturizing cream

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Drinks with active ingredients Rosa Roxburghii and Pomegranate
Description: Take drinks with active ingredients such as Rosa Roxburghii and Pomegranate. Drink every morning on an empty stomach, 20ml/2 sachets/day.
Study: NCT04529512

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DEXTENZA®
Description: DEXTENZA® is a corticosteroid implant indicated for the treatment of ocular pain following ophthalmic surgery. DEXTENZA® is inserted into the lower lacrimal punctum into the canaliculus by the physician following ophthalmic surgery. A single DEXTENZA® releases a 0.4 mg dose of dexamethasone for up to 30 days following insertion. DEXTENZA® is preservative free, resorbable and does not require removal. Saline irrigation or manual expression can be performed to remove the insert, if necessary.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DEXTENZA®
Description: DEXTENZA® is a corticosteroid implant indicated for the treatment of ocular pain following ophthalmic surgery. DEXTENZA® is inserted into the lower lacrimal punctum into the canaliculus by the physician following ophthalmic surgery. A single DEXTENZA® releases a 0.4 mg dose of dexamethasone for up to 30 days following insertion. DEXTENZA® is preservative free, resorbable and does not require removal. Saline irrigation or manual expression can be performed to remove the insert, if necessary.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DEXTENZA®
Description: DEXTENZA® is a corticosteroid implant indicated for the treatment of ocular pain following ophthalmic surgery. DEXTENZA® is inserted into the lower lacrimal punctum into the canaliculus by the physician following ophthalmic surgery. A single DEXTENZA® releases a 0.4 mg dose of dexamethasone for up to 30 days following insertion. DEXTENZA® is preservative free, resorbable and does not require removal. Saline irrigation or manual expression can be performed to remove the insert, if necessary.
Study: NCT05569928

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Administration of deuterated compounds for kinetic study
Description: Participants will be submitted to a standardized oral-fat load and kinetic study will be performed

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Administration of deuterated compounds for kinetic study
Description: Participants will be submitted to a standardized oral-fat load and kinetic study will be performed

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Administration of deuterated compounds for kinetic study
Description: Participants will be submitted to a standardized oral-fat load and kinetic study will be performed
Study: NCT04893356

Intervention type: GENETIC
Intervention: O6-methylguanine-DNA methyltransferase (MGMT) promoter methylation and MGMT expression on dacarbazine treated sarcoma patients
Description: Tumor samples of Leiomyosarcoma and Solitary Fibrous Tumours patients, dacarbazine (as single agents or in combination with anthracyclines) treated, will be obtained from and characterized by the Pathology Unit of the Istituto Nazionale Tumori Fondazione Pascale in Naples, Campus Biomedico of Rome, Istituto Oncologico of Bari and University of Palermo.~Glioblastomas control samples will be obtained from CEINGE-Biotecnologie Avanzate, in Naples and characterized by the Pathology Unit of the University of Naples Federico II.~After biopsy or surgical resection, the tissues were fixed in 10% formalin and included in paraffin blocks. All patients partecipating in this study provided informed consent.
Study: NCT04687020

Intervention type: DRUG
Group type: OTHER
Intervention: Viltolarsen
Description: Received during weekly intravenous infusions
Study: NCT06408064

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Music therapy
Description: Music therapy is a non-pharmacological therapeutic intervention that will be implemented through two modalities: live and pre-recorded instrumental lullabies music.The volume control will be conducted within the groups through the use of a decibel regulator, with a maximum volume of 70 dB. During the intervention and for a period of 30 minutes following its conclusion, singing will be prohibited by the music therapist or the parents. Both live and pre-recorded music will be instrumental in nature, lacking any lyrics.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Music therapy
Description: Music therapy is a non-pharmacological therapeutic intervention that will be implemented through two modalities: live and pre-recorded instrumental lullabies music.The volume control will be conducted within the groups through the use of a decibel regulator, with a maximum volume of 70 dB. During the intervention and for a period of 30 minutes following its conclusion, singing will be prohibited by the music therapist or the parents. Both live and pre-recorded music will be instrumental in nature, lacking any lyrics.
Study: NCT04801472

Intervention type: OTHER
Group type: OTHER
Intervention: Optimisation of dental implant sites protection from irradiation
Description: Optimal treatment plan validation after two dosimetric computer-tomography scans (with or without radiological guide) and visualisation of virtual dental implants on scanner images.~Evaluation of toxicity, quality of life and dental implant survival rate
Study: NCT04147624

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Souvenaid
Description: Souvenaid is an oral beverage that contains a vitamin mixture (Vitamin A, B1, B2, B3, B5, D) plus three main active ingredients: omega-3 fatty acids, uridine monophosphate, and choline.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The Placebo used in this study is an oral beverage vitamin mixture containing Vitamins A, B1, B2, B3 and B5.
Study: NCT05998434

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Improving Low Back Pain Through Motor Control Training
Description: In the digital healthcare group, participants utilized app-based online motor control training. In contrast, participants in the traditional treatment group underwent motor control training under the guidance of healthcare professionals at the hospital.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Improving Low Back Pain Through Motor Control Training
Description: In the digital healthcare group, participants utilized app-based online motor control training. In contrast, participants in the traditional treatment group underwent motor control training under the guidance of healthcare professionals at the hospital.
Study: NCT05808062

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Root canal obturation
Description: Root canal dryness

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Root canal obturation
Description: Root canal dryness
Study: NCT05686681

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief Behavioral Activation for Improving Social Connectedness
Description: Brief Behavioral Activation for Improving Social Connectedness (BBAISC): BBAISC was developed to address social connectedness. Grounded in Behavioral Activation (Lejuez et al., 2011), BBAISC is a structured, 6-session skill-building intervention that has 4 key elements (Pepin et al., 2020):~1. Psychoeducation: Psychoeducation focused on homebound status, social connectedness, and associated changes in behavior.~2. Behavioral Activation intervention rationale: Framing how changing behavior can positively impact social connectedness (i.e., improve social connectedness and reduce loneliness).~3. Exploration of life areas, values, and activities: Focused on identifying life areas and values most relevant to the participant. Then, these values are used to generate activities that are aligned with those values.~4. Activity monitoring and planning: Participants are encouraged to schedule and organize their day based on what is important rather than their current mood or feeling state.
Study: NCT05645900

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Quadrivalent influenza virus subunit vaccine
Description: This vaccine（0.5ml） is produced by Ab\&b Biotechnology Co., Ltd.JS。Subjects will receive two doses of quadrivalent influenza virus subunit vaccine administered 28 days apart by intramuscular injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Quadrivalent influenza virus subunit vaccine
Description: This vaccine（0.25ml） is produced by Ab\&b Biotechnology Co., Ltd.JS。Subjects will receive two doses of quadrivalent influenza virus subunit vaccine administered 28 days apart by intramuscular injection

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Quadrivalent split influenza virus vaccine
Description: This vaccine（0.25ml） is produced by HUALAN BIO。Subjects will receive two doses of quadrivalent split influenza virus vaccine administered 28 days apart by intramuscular injection
Study: NCT04977362

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Enhanced Recovery After Surgery
Description: Enhanced recovery after surgery is a multimodal, transdisciplinary care approach for patients undergoing surgical procedures. It is implemented in various surgical specialties, among others in cardiac surgery. The care approach aims at promotion of recovery of the patients throughout their perioperative process, reduction of complications, and early return to normal activities.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as Usual
Description: treatment as usual according to standard care in heart valve surgery
Study: NCT05249309

Intervention type: DRUG
Intervention: Ketamine
Description: The administration will be done subcutaneously, in the abdominal wall, using ketamine without dilution. The ketamine dose will be 0.5mg/kg, recommended for the first infusion. If there is no adequate response, according to psychiatric scales and clinical evaluation, the second infusion must be performed at least two days after the first, using 0.75mg/kg and the subsequent 1mg/kg. If the patient adequately responds to a dose (0.5 or 0.75mg/kg), it should be repeated after over twice weekly over a period of 4 weeks.
Study: NCT05124002

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Recombinant Human Adenovirus Type 5
Description: H101 will be intratumorally injected 3 days before HAIC. Dosage of H101: 1 vial (5.0 × 10\^11 vp) if the maximum diameters of lesion ≤ 5 cm, 2 vials (1.0 × 10\^12 vp) if the maximum diameters of lesion ≤ 10 cm, 3 vials (1.5 × 10\^12 vp) if the maximum diameters of lesion is \> 10 cm.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HAIC of FOLFOX
Description: Oxaliplatin 50 mg + 5-FU 1.5 g + leucovorin calcium. The infusion will be continued for 2-3 days according to patients' tolerance and tumor conditions. The standard treatment for HAIC consists of 4-6 cycles, with the second cycle being 3 weeks after the end of the first HAIC cycle and the subsequent cycles being 4 weeks after the end of the previous HAIC.
Study: NCT05514210

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: heart team meeting and discussion
Description: When the patient is eligible for the study, the interventional cardiologist will invite a cardiac surgeon to conduct a heart team discussion. Both specialists will assess the patient comprehensively and make an optimal decision for the patient, with consideration patient's preference.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: heart team meeting and discussion
Description: When the patient is eligible for the study, the interventional cardiologist will invite a cardiac surgeon to conduct a heart team discussion. Both specialists will assess the patient comprehensively and make an optimal decision for the patient, with consideration patient's preference.
Study: NCT00766285

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Trivalent inactivated influenza vaccine
Description: Standard trivalent influenza vaccine consisting of 15 mcg per antigen (45 mcg total) by intramuscular deltoid injection.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Trivalent Baculovirus-expressed Influenza HA vaccine
Description: Influenza virus hemagglutinin proteins expressed in insect (SF+) cells under serum free conditions by recombinant baculovirus.
Study: NCT04673656

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: BKR-017
Description: Nutrient butyrate into a colon-targeted tablet formulation (BKR-017) is intended to stimulate secretion of GLP-1 from L-cells in the lower gut. Butyrate delivered to the colon in tablet form will not cause the side-effects seen with formation of butyrate by fermentation.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: BKR-017
Description: Nutrient butyrate into a colon-targeted tablet formulation (BKR-017) is intended to stimulate secretion of GLP-1 from L-cells in the lower gut. Butyrate delivered to the colon in tablet form will not cause the side-effects seen with formation of butyrate by fermentation.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: BKR-017
Description: Nutrient butyrate into a colon-targeted tablet formulation (BKR-017) is intended to stimulate secretion of GLP-1 from L-cells in the lower gut. Butyrate delivered to the colon in tablet form will not cause the side-effects seen with formation of butyrate by fermentation.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: BKR-017
Description: Nutrient butyrate into a colon-targeted tablet formulation (BKR-017) is intended to stimulate secretion of GLP-1 from L-cells in the lower gut. Butyrate delivered to the colon in tablet form will not cause the side-effects seen with formation of butyrate by fermentation.
Study: NCT06028334

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: GetUp&Go
Description: A behavioral treatment combining personalized activity planning and a mobile health application for supporting adherence to activity plans.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: GetUp&Go with 10-Week Delay
Description: No assigned treatment during the waitlist phase. Participants in the WL group will be offered the GetUp\&Go intervention, which combines personalized activity planning and a mobile health application, after collection of the primary outcome measure.
Study: NCT05032742

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: mHealth parenting stress app
Description: mHealth parenting stress app intervention to reduce parenting stress and improving youth community-based treatment engagement.